J&J cuts one of its four business units

Another restructuring is underway at Johnson & Johnson. The company is collapsing one of its four units--the "comprehensive-care" business, which marketed diabetes, vision and heart-related products--and parceling out the pieces to the three remaining. No word yet on what's ahead for the management and staff in those pieces of the business.

Donald Casey, who's been worldwide chairman of comprehensive care, will be overseeing the breakup and transfer. "Announcements about Don's future role, and other personnel and organizational announcements, will be made on an ongoing basis as this transition planning progresses over the next several weeks," J&J spokesman Bill Price told Dow Jones. Price credited the "challenging business and economic environment" for the management consolidation.

As you know, this makes two management shuffles for J&J over the past two years. The company reorganized its business in late 2007, and that's when the comprehensive care unit was created. It's not the first element of the 2007 overhaul to die, however; J&J folded its office of strategy and growth earlier this year.

- see the Dow Jones piece

ALSO: Johnson & Johnson warned doctors of reports of a deadly skin reaction and liver failure in patients using its HIV medicine Intelence. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.